Targeting defective tau proteins may be needed to treat Alzheimer's patients
In November, researchers reported the drug lecanemab slowed the progression of Alzheimer's disease. The effect was modest, but it has generated tremendous excitement because it was the first time a drug had been shown to be able to affect the course of this relentless, incurable disease.
Randall Eck Brian Kraemer Emily Henderson Division Of Gerontology Geriatric Medicine Uw Graduate Program In Neuroscience University Of Washington School Medicine
Source: news-medical.net